BACKGROUND Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Extragastrointestinal stromal tumors (eGISTs) of the mesoileum are extremely rare and are usually treated with surgery combined with imatinib therapy. CASE PRESENTATION We present the case of a 43-year-old man who developed a large eGIST in the mesoileum. Abdominal/pelvic c...

BACKGROUND AND OBJECTIVES We aim to analyze the impact of chemotherapy timing on surgical site infections (SSI) after immediate breast reconstruction (IBR). METHODS A retrospective review of patients undergoing IBR between 2010 and 2015 was performed. Patients were divided into four groups: those with neoadjuvant chemotherapy only, adjuvant chemotherapy only, both adjuvant and neoadjuvant, an...

•We present a case of cervical large cell neuroendocrine carcinoma (LCNEC) and neoadjuvant chemotherapy with irinotecan plus cisplatin that was extremely effective.•Cervical LCNEC is uncommon and highly aggressive, and optimal therapy has yet to be determined.•This case suggests that neoadjuvant chemotherapy followed by radical hysterectomy could be a useful treatment option for bulky cervical ...

We report 2 cases of primary breast cancer with swelling of the parasternal lymph nodes detected on diŠusion-weighted imaging (DWI) as small parasternal nodules. After neoadjuvant chemotherapy, DWI showed disappearance of one node but a focus of subtle signal hyperintensity in the other. DWI ˆndings correlated with the results of conventional breast contrast-enhanced magnetic resonance imaging ...

BACKGROUND Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to benefit, we evaluated germline pharmacogenomic markers for association with ...

We have prospectively validated in an independent clinical cohort the finding that elevated amounts of tumor-infiltrating lymphocytes in breast carcinoma tissues predict the response of patients to neoadjuvant chemotherapy. These results suggest that a robust tumor infiltration by T and B cells is a promising biomarker to define patients who might benefit from neoadjuvant chemotherapy.

Neoadjuvant cisplatin-based chemotherapy has been widely used in the last decade for organ preservation or unresectable disease in advanced stage head and neck cancer. We examined the expression of a series of tumor markers that have been associated with chemotherapy resistance in pretreatment biopsies from 68 patients who received cisplatin-based neoadjuvant chemotherapy at either of two insti...

Neoadjuvant chemotherapy is standard management for women who have locally advanced or inflammatory breast cancer, but can be applied to all women who may require postoperative chemotherapy for early-stage breast cancer. Disease-free survival and overall survival are equivalent between patients treated with neoadjuvant chemotherapy and patients treated with the same regimen postoperatively. Pre...

BACKGROUND This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma. METHODS A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesoph...

Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, hormone receptor positive (especially human epidermal growth 2 negative) cancer show low response rate to neoadjuvant chemotherapy. Whether chemo-endocrine therapy (NCET) can improve pathological complete (pCR) of these remains controversial. Methods: A systematic li...